Daré Bioscience Announces Publication In The Journal Of The North American Menopause Society Of Efficacy Findings For the Treatment Of Menopausal Symptoms From A Phase 1/2 Clinical Trial Of DARE-HRT1 Intravaginal Rings
Portfolio Pulse from Benzinga Newsdesk
Daré Bioscience has announced positive preliminary efficacy results from its Phase 1/2 clinical study of DARE-HRT1, a treatment for menopausal symptoms, in healthy postmenopausal women. The study found that DARE-HRT1 demonstrated preliminary treatment efficacy for both Vasomotor Symptoms (VMS) and Genitourinary Syndrome of Menopause (GSM). Daré plans to advance DARE-HRT1 into a single Phase 3 efficacy trial for the treatment of VMS due to menopause. If successful, DARE-HRT1 could be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy.
August 09, 2023 | 12:24 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Positive preliminary results from Daré Bioscience's Phase 1/2 clinical study of DARE-HRT1 could potentially boost investor confidence in the company. The advancement of DARE-HRT1 into a Phase 3 trial could also have a positive impact on the company's stock.
The positive preliminary results from the Phase 1/2 clinical study of DARE-HRT1 indicate that the treatment is effective, which could increase investor confidence in the company. The announcement that Daré Bioscience plans to advance DARE-HRT1 into a Phase 3 trial could also be seen as a positive development, potentially leading to an increase in the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100